TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HELP Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate DX-2930 For Long-Term Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)
Brief Summary: This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of DX-2930 in preventing acute angioedema attacks in patients with Type I and Type II HAE.


Options:
A: Arm Label: SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2; Type: EXPERIMENTAL; Interventions: Biological: CINRYZE with rHuPH20 | Arm Label: SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1; Type: EXPERIMENTAL; Interventions: Biological: CINRYZE with rHuPH20 | Intervention Type: BIOLOGICAL; Name: CINRYZE with rHuPH20; Assigned to Arm(s): SC CINRYZE with rHuPH20 Dose Level 1 followed by Dose Level 2, SC CINRYZE with rHuPH20 Dose Level 2 followed by Dose Level 1
B: Arm Label: BCX7353 110 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 capsules | Arm Label: BCX7353 150 mg once daily; Type: EXPERIMENTAL; Interventions: Drug: BCX7353 capsules | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo oral capsule | Intervention Type: DRUG; Name: BCX7353 capsules; Assigned to Arm(s): BCX7353 110 mg once daily, BCX7353 150 mg once daily | Intervention Type: DRUG; Name: Placebo oral capsule; Assigned to Arm(s): Placebo
C: Arm Label: DX-2930 300 mg every 2 weeks; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 - 300mg/2wk | Arm Label: DX-2930 300 mg every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 - 300mg/4wk | Arm Label: DX-2930 150 mg every 4 weeks; Type: EXPERIMENTAL; Interventions: Drug: DX-2930 - 150mg/4wk | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: DX-2930 - 300mg/2wk; Assigned to Arm(s): DX-2930 300 mg every 2 weeks | Intervention Type: DRUG; Name: DX-2930 - 300mg/4wk; Assigned to Arm(s): DX-2930 300 mg every 4 weeks | Intervention Type: DRUG; Name: DX-2930 - 150mg/4wk; Assigned to Arm(s): DX-2930 150 mg every 4 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: CSL312 (low); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Arm Label: CSL312 (med); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Arm Label: CSL312 (high); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Arm Label: CSL312 (med/high); Type: ACTIVE_COMPARATOR; Interventions: Biological: Factor XIIa antagonist monoclonal antibody | Intervention Type: BIOLOGICAL; Name: Factor XIIa antagonist monoclonal antibody; Assigned to Arm(s): CSL312 (high), CSL312 (low), CSL312 (med), CSL312 (med/high) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Investigation of the Gather mHealth Platform on Diabetics' Behavior and Health Outcomes.
Brief Summary: The purpose of this trial is to explore the impact of the Gather Health diabetes management platform diabetics' health behaviors and health outcomes and how providers and diabetics interact with the Gather Health platform.


Options:
A: Arm Label: Gather app; Type: EXPERIMENTAL; Interventions: Other: Gather app | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Gather app; Assigned to Arm(s): Gather app
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): 1
C: Arm Label: Integrated Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Integrated Behavioral Care | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Integrated Behavioral Care; Assigned to Arm(s): Integrated Behavioral Intervention
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Home Telehealth with Behavioral Education Component | Intervention Type: BEHAVIORAL; Name: Home Telehealth with Behavioral Education Component; Assigned to Arm(s): Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors
Brief Summary: A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the efficacy of Surufatinib 300 mg once a day in treating advanced extrapancreatic neuroendocrine tumors.


Options:
A: Arm Label: lanreotide; Type: EXPERIMENTAL; Interventions: Drug: lanreotide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lanreotide; Assigned to Arm(s): lanreotide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Everolimus 10 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus 10 mg/day | Intervention Type: DRUG; Name: Everolimus Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Surufatinib; Type: EXPERIMENTAL; Interventions: Drug: Surufatinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Surufatinib; Assigned to Arm(s): Surufatinib | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 250 mg Telotristat Etiprate; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo-matching telotristat etiprate | Arm Label: 500 mg Telotristat Etiprate; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo-matching telotristat etiprate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo-matching telotristat etiprate | Arm Label: Telotristat Etiprate Open-Label Extension; Type: EXPERIMENTAL; Interventions: Drug: Telotristat etiprate, Drug: Placebo-matching telotristat etiprate | Intervention Type: DRUG; Name: Telotristat etiprate; Assigned to Arm(s): 250 mg Telotristat Etiprate, 500 mg Telotristat Etiprate, Telotristat Etiprate Open-Label Extension | Intervention Type: DRUG; Name: Placebo-matching telotristat etiprate; Assigned to Arm(s): 250 mg Telotristat Etiprate, 500 mg Telotristat Etiprate, Placebo, Telotristat Etiprate Open-Label Extension

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Study Protocol for a Randomized, Placebo-controlled Trial
Brief Summary: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) affects many adult men worldwide. So far, available therapies offer little or no proven benefit to CP/CPPS. The investigators design and implement this study is to assess efficacy of acupuncture therapy performed in the CP/CPPS .


Options:
A: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
B: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
C: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Device: Acupuncture | Arm Label: placebo needle; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo needle | Intervention Type: DEVICE; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: DEVICE; Name: placebo needle; Assigned to Arm(s): placebo needle
D: Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Acupuncture for Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Study Protocol for a Randomized, Placebo-controlled Trial
Brief Summary: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) affects many adult men worldwide. So far, available therapies offer little or no proven benefit to CP/CPPS. The investigators design and implement this study is to assess efficacy of acupuncture therapy performed in the CP/CPPS .


Options:
A: Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: dustasteride arm; Type: EXPERIMENTAL; Interventions: Drug: Dutasteride | Intervention Type: DRUG; Name: Dutasteride; Assigned to Arm(s): dustasteride arm | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Arm
B: Arm Label: Global Therapeutic Massage (GTM); Type: PLACEBO_COMPARATOR; Interventions: Other: Global Therapeutic Massage (GTM) | Arm Label: Myofascial physical therapy (MPT); Type: ACTIVE_COMPARATOR; Interventions: Other: Myofascial physical therapy (MPT) | Intervention Type: OTHER; Name: Global Therapeutic Massage (GTM); Assigned to Arm(s): Global Therapeutic Massage (GTM) | Intervention Type: OTHER; Name: Myofascial physical therapy (MPT); Assigned to Arm(s): Myofascial physical therapy (MPT)
C: Intervention Type: PROCEDURE; Name: Acupuncture; Assigned to Arm(s): N/A
D: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Device: Acupuncture | Arm Label: placebo needle; Type: PLACEBO_COMPARATOR; Interventions: Device: placebo needle | Intervention Type: DEVICE; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: DEVICE; Name: placebo needle; Assigned to Arm(s): placebo needle

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Supported Discharge for Improving Functional Outcomes After Stroke
Brief Summary: The purpose of this pragmatic study is to investigate whether implementation of a comprehensive post-acute stroke service model that integrates Early Supported Discharge (ESD) and Transitional Care Management (TCM) for stroke survivors discharged home improves functional outcomes post-stroke, reduces caregiver stress, and reduces readmission rates.


Options:
A: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: COMPASS Intervention; Type: ACTIVE_COMPARATOR; Interventions: Other: COMPASS Intervention | Intervention Type: OTHER; Name: COMPASS Intervention; Assigned to Arm(s): COMPASS Intervention
B: Arm Label: Improvement intervention; Type: OTHER; Interventions: Behavioral: improvement intervention | Arm Label: no intervention; Type: OTHER; Interventions: Behavioral: no intervention | Intervention Type: BEHAVIORAL; Name: improvement intervention; Assigned to Arm(s): Improvement intervention | Intervention Type: BEHAVIORAL; Name: no intervention; Assigned to Arm(s): no intervention
C: Arm Label: an intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Behaviour Change Wheel model guided intervention | Arm Label: a control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behaviour Change Wheel model guided intervention; Assigned to Arm(s): an intervention arm
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Information feedback | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information feedback | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 1 | Intervention Type: BEHAVIORAL; Name: Information feedback; Assigned to Arm(s): Arm 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Trial of Radiofrequency Ablation vs Conventional Surgery for Superficial Venous Insufficiency: if You Don't Tell, They Won't Know
Brief Summary: The current study was a double blind randomised controlled trial that compared radiofrequency ablation (RFA) versus conventional surgery (CS) in patients who served as their own controls and who had intact great saphenous veins (GSVs).


Options:
A: Arm Label: VenaSeal SCS; Type: EXPERIMENTAL; Interventions: Device: VenaSeal SCS | Arm Label: RFA (ClosureFast); Type: ACTIVE_COMPARATOR; Interventions: Device: ClosureFast Radiofrequency Ablation (RFA) | Arm Label: Roll-in (VenaSeal SCS); Type: EXPERIMENTAL; Interventions: Device: Roll-in (VenaSeal SCS) | Intervention Type: DEVICE; Name: VenaSeal SCS; Assigned to Arm(s): VenaSeal SCS | Intervention Type: DEVICE; Name: ClosureFast Radiofrequency Ablation (RFA); Assigned to Arm(s): RFA (ClosureFast) | Intervention Type: DEVICE; Name: Roll-in (VenaSeal SCS); Assigned to Arm(s): Roll-in (VenaSeal SCS)
B: Arm Label: MOCA; Type: EXPERIMENTAL; Interventions: Procedure: MOCA | Arm Label: EVLA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: EVLA | Arm Label: RFA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: RFA | Intervention Type: PROCEDURE; Name: MOCA; Assigned to Arm(s): MOCA | Intervention Type: PROCEDURE; Name: EVLA; Assigned to Arm(s): EVLA | Intervention Type: PROCEDURE; Name: RFA; Assigned to Arm(s): RFA
C: Arm Label: high ligation and stripping; Type: ACTIVE_COMPARATOR; Interventions: Procedure: high ligation and stripping (surgery) | Arm Label: duplex guided foam sclerotherapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: FOAM | Intervention Type: PROCEDURE; Name: high ligation and stripping (surgery); Assigned to Arm(s): high ligation and stripping | Intervention Type: PROCEDURE; Name: FOAM; Assigned to Arm(s): duplex guided foam sclerotherapy
D: Arm Label: Conventional Surgery; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Conventional Surgery | Arm Label: Radiofrequency Ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radiofrequency Ablation | Intervention Type: PROCEDURE; Name: Conventional Surgery; Assigned to Arm(s): Conventional Surgery | Intervention Type: PROCEDURE; Name: Radiofrequency Ablation; Assigned to Arm(s): Radiofrequency Ablation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Individualized Management Based on Mobile Phone Platform in Diabetic Patients
Brief Summary: The purpose of this study was to explore a model suitable for the individualized diabetic management based on the mobile application coaching and demonstrate its effect among the diabetic mellitus population.


Options:
A: Arm Label: PHCVRS intervention; Type: EXPERIMENTAL; Interventions: Other: PHCVRS Intervention, Other: Personal Health Record | Arm Label: Usual care/Personal Health Record; Type: OTHER; Interventions: Other: Personal Health Record | Intervention Type: OTHER; Name: PHCVRS Intervention; Assigned to Arm(s): PHCVRS intervention | Intervention Type: OTHER; Name: Personal Health Record; Assigned to Arm(s): PHCVRS intervention, Usual care/Personal Health Record
B: Arm Label: Information on community resources; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Community Health Worker services; Type: EXPERIMENTAL; Interventions: Behavioral: Community Health Worker (CHW) services | Intervention Type: BEHAVIORAL; Name: Community Health Worker (CHW) services; Assigned to Arm(s): Community Health Worker services
C: Arm Label: online mutual management; Type: EXPERIMENTAL; Interventions: Device: Welltang App | Arm Label: online self-management; Type: EXPERIMENTAL; Interventions: Device: Welltang App | Arm Label: hospital regular management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Welltang App; Assigned to Arm(s): online mutual management, online self-management
D: Arm Label: Comprehensive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Changes, Drug: Antiplatelet Agents, Drug: Beta Blocker, Drug: ACE Inhibitors | Arm Label: Less Intensive Intervention Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle Changes | Intervention Type: BEHAVIORAL; Name: Lifestyle Changes; Assigned to Arm(s): Comprehensive Intervention Group, Less Intensive Intervention Group | Intervention Type: DRUG; Name: Antiplatelet Agents; Assigned to Arm(s): Comprehensive Intervention Group | Intervention Type: DRUG; Name: Beta Blocker; Assigned to Arm(s): Comprehensive Intervention Group | Intervention Type: DRUG; Name: ACE Inhibitors; Assigned to Arm(s): Comprehensive Intervention Group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Controlled, Open-Label, Phase II-III Trial to Evaluate the Safety and Efficacy of Regimens Containing Bedaquiline and Pretomanid for the Treatment of Adult Patients With Pulmonary Multidrug Resistant Tuberculosis
Brief Summary: TB PRACTECAL is a multi-centre, open label, multi-arm, randomised, controlled, phase II-III trial; evaluating short treatment regimens containing bedaquiline and pretomanid in combination with existing and re-purposed anti-TB drugs for the treatment of biologically confirmed pulmonary multi drug-resistant TB (MDR-TB).


Options:
A: Arm Label: HIV infected; Type: EXPERIMENTAL; Interventions: Drug: INH, Rifampicin, Ethambutol and Pyrazinamide | Arm Label: HIV negative; Type: ACTIVE_COMPARATOR; Interventions: Drug: INH, Rifampicin, Ethambutol and Pyrazinamide | Intervention Type: DRUG; Name: INH, Rifampicin, Ethambutol and Pyrazinamide; Assigned to Arm(s): HIV infected | Intervention Type: DRUG; Name: INH, Rifampicin, Ethambutol and Pyrazinamide; Assigned to Arm(s): HIV negative
B: Arm Label: Regimen 1; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Pretomanid, Drug: Moxifloxacin, Drug: Linezolid | Arm Label: Regimen 2; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Pretomanid, Drug: Linezolid, Drug: Clofazimine | Arm Label: Regimen 3; Type: EXPERIMENTAL; Interventions: Drug: Bedaquiline, Drug: Pretomanid, Drug: Linezolid | Arm Label: Control Regimen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB. | Intervention Type: DRUG; Name: Bedaquiline; Assigned to Arm(s): Regimen 1, Regimen 2, Regimen 3 | Intervention Type: DRUG; Name: Pretomanid; Assigned to Arm(s): Regimen 1, Regimen 2, Regimen 3 | Intervention Type: DRUG; Name: Moxifloxacin; Assigned to Arm(s): Regimen 1 | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Regimen 1, Regimen 2, Regimen 3 | Intervention Type: DRUG; Name: Clofazimine; Assigned to Arm(s): Regimen 2 | Intervention Type: DRUG; Name: Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.; Assigned to Arm(s): Control Regimen
C: Arm Label: Delayed Start Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Delayed Start Linezolid | Arm Label: Immediate Start Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Immediate Start Linezolid | Intervention Type: DRUG; Name: Immediate Start Linezolid; Assigned to Arm(s): Immediate Start Linezolid | Intervention Type: DRUG; Name: Delayed Start Linezolid; Assigned to Arm(s): Delayed Start Linezolid
D: Arm Label: Linezolid; Type: EXPERIMENTAL; Interventions: Drug: Linezolid | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Multi-center Phase III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Placebo in Patients With Advanced Pancreatic Neuroendocrine Tumors
Brief Summary: A randomized, double-blind, placebo controlled, multi-center Phase III study to assess the efficacy of Surufatinib 300 mg once a day in treating advanced pancreatic neuroendocrine tumors.


Options:
A: Arm Label: lanreotide; Type: EXPERIMENTAL; Interventions: Drug: lanreotide | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: lanreotide; Assigned to Arm(s): lanreotide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Arm Label: Surufatinib; Type: EXPERIMENTAL; Interventions: Drug: Surufatinib | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Surufatinib; Assigned to Arm(s): Surufatinib | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Everolimus 10 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Everolimus | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Everolimus Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus 10 mg/day | Intervention Type: DRUG; Name: Everolimus Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Octreotide+ Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Octreotide, Drug: Everolimus | Arm Label: Octreotide+ Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Octreotide, Drug: Placebo | Intervention Type: DRUG; Name: Octreotide; Assigned to Arm(s): Octreotide+ Everolimus, Octreotide+ Placebo | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Octreotide+ Placebo | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Octreotide+ Everolimus

Answer: B